Table 1.
Demographics of melanoma patients with LMD.
| Age | Sex | Diagnosis | Location in the CNS | Pre-Op treatment |
|---|---|---|---|---|
| 57 | F | Melanoma/LMD | Cerebellum | Dabrafenib, Trametinib |
| 29 | M | Melanoma/LMD | Cerebellum | Chemotherapy |
| 38 | F | Melanoma/LMD | Occipital lobe | None |
| 74 | F | Melanoma/LMD | Temporal lobe | None |
| 63 | F | Melanoma/LMD | Cerebellum | Chemotherapy, IL-2, Ipilimumab |
| 62 | M | Melanoma/LMD | Occipital Lobe | Radiosurgery, Ipilimumab, Nivolumab |
| 45 | M | Melanoma/LMD | Temporal lobe | Allogeneic vaccine, whole brain radiation, chemotherapy |
| 57 | M | Melanoma/LMD | Frontal Lobe | Radiosurgery, Pembrolizumab, Dabrafenib |